These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33966475)

  • 1. Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies.
    Meca-Lallana J; García-Merino JA; Martínez-Yélamos S; Vidal-Jordana A; Costa L; Eichau S; Rovira À; Brieva L; Agüera E; Zarranz AR
    Neurodegener Dis Manag; 2021 Jun; 11(3):251-261. PubMed ID: 33966475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly active disease and access to disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Poland.
    Brola W; Adamczyk-Sowa M; Kułakowska A; Głażewska J; Smaga A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2022; 56(3):256-260. PubMed ID: 35766058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2023 Sep; 16(5):457-471. PubMed ID: 37072663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
    Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
    Lenz F; Harms L
    Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice.
    Bourre B; Casez O; Ciron J; Gueguen A; Kwiatkowski A; Moisset X; Montcuquet A; Ayrignac X
    Rev Neurol (Paris); 2023 Apr; 179(4):256-264. PubMed ID: 36621364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.
    Vermersch P; Oh J; Cascione M; Oreja-Guevara C; Gobbi C; Travis LH; Myhr KM; Coyle PK
    Mult Scler Relat Disord; 2020 Aug; 43():102158. PubMed ID: 32470857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study.
    Sippel A; Riemann-Lorenz K; Scheiderbauer J; Kleiter I; Morrison R; Kofahl C; Heesen C
    BMC Health Serv Res; 2021 Oct; 21(1):1141. PubMed ID: 34686166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.
    Grand'Maison F; Yeung M; Morrow SA; Lee L; Emond F; Ward BJ; Laneuville P; Schecter R
    Curr Med Res Opin; 2018 Aug; 34(8):1419-1430. PubMed ID: 29583054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment.
    Zanghì A; D'Amico E; Patti F
    Expert Rev Neurother; 2020 Aug; 20(8):771-782. PubMed ID: 31971026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.
    Eskyte I; Manzano A; Pepper G; Pavitt S; Ford H; Bekker H; Chataway J; Schmierer K; Meads D; Webb E; Potrata B
    Mult Scler Relat Disord; 2019 Jan; 27():370-377. PubMed ID: 30476873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
    Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
    Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
    McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
    Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    Pardo G; Jones DE
    J Neurol; 2017 Dec; 264(12):2351-2374. PubMed ID: 28879412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: A network meta-analysis.
    Lucchetta RC; Leonart LP; Becker J; Pontarolo R; Fernandez-Llimós F; Wiens A
    Mult Scler Relat Disord; 2019 Oct; 35():7-15. PubMed ID: 31276913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.